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Ovarian hyperstimulation syndrome (OHSS) is a serious complication of controlled ovarian hyperstimulation (COH).
The syndrome almost always presents either after hCG administration in susceptible patients or during early
pregnancy. Despite many years of clinical experience, there are no precise methods to completely prevent severe
OHSS, except by withholding the ovulation-inducing trigger of hCG. Recently, COH which combining GnRH
antagonist co-treatment and GnRH agonist trigger has become a common tool aiming to eliminate severe
early OHSS. However, the observed decrease in implantation and pregnancy rates following this approach has
encouraged different modifications of luteal support aiming to improve outcome. One of the suggest approach is the
1500 IU hCG luteal rescue, which appears to be a promising protocol, aiming to reduce (rather than eliminating) severe
early OHSS, without compromising outcome. In the present paper we discuss the different suggested strategies and
offer a strict triage, aimed at eliminating the occurrence of severe OHSS based on several clinical observations,
including the role of GnRH-antagonist in COH protocols, the use of different luteal rescue protocols and the ability to
transfer embryos in the blastocyst stage.
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Ovarian hyperstimulation syndrome (OHSS) is a serious
complication of ovulation induction, almost always pre-
sents either after hCG administration in susceptible pa-
tients or during early pregnancy. Its cardinal features are
marked ovarian enlargement and an increase in capillary
permeability, with the consequent acute third-space fluid
sequestration and its related morbidity [1]. Despite many
years of clinical experience, the pathophysiology of OHSS
is poorly understood, there is no reliable test to predict
patients who will subsequently develop severe OHSS [2]
and there are no precise methods to completely prevent
severe OHSS.
Ideally, assisted reproduction technology (ART) practi-
tioners seek a balance between optimum ovarian stimula-
tion and successful treatment outcome with minimal rate
of severe OHSS or multiple pregnancies. Individualization
of treatment according to the specific risk factor and the
specific response in the current cycle with the option ofCorrespondence: raoul.orvieto@sheba.health.gov.il
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reproduction in any medium, provided the orfreezing of all embryos, or replacement of only a single
embryo, has the potential of reducing the risk and the
severity of the syndrome in susceptible cases. Moreover,
while withholding the ovulation-inducing trigger of hCG,
or replacing hCG with GnRH agonist (GnRHa) to trigger
ovulation [3], may eliminate severe early OHSS, these
methods are associated with decrease reproductive
outcome.
GnRHa trigger
Controlled ovarian hyperstimulation (COH) which com-
bines GnRH antagonist co-treatment and GnRHa trigger
has recently become a common tool aiming to eliminate
severe early OHSS and to support the concept of an
OHSS-free clinic [4,5]. However, due to the reported
significantly reduced clinical pregnancy and increased first
trimester pregnancy loss [6,7], efforts have been made to
improve reproductive outcome, by manipulating the luteal
phase. While discussing the recent developments in GnRHa
trigger, Kol and Humaidan [8] presented 3 optional strat-
egies aiming to improve outcome: freeze-all policy; freshThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and low-dose HCG supplementation.
Freeze-all policy is offered in extreme cases [5] in an at-
tempt to ensure OHSS risk-free and maintain a reasonable
cumulative pregnancy rate [9]. However, despite the recent
improvement in live birth rates after replacement of
frozen-thawed vitrified oocytes/embryos, it should be
emphasized, that in most centers, there is still a gap in
live birth rates between fresh and frozen/thawed cycles
(in favour of fresh cycle).
Intensive luteal support of estradiol (E2) and progesterone,
as described by Engmann et al. [10]. The data regarding
the efficacy of luteal phase rescue after GnRHa trigger
followed by intensive luteal phase support are intriguingly
conflicting. We compared our experience with GnRHa
trigger before [7] and after modifying our luteal-phase
support to the intensive support with E2 and progesterone
similar to the one reported by Engmann et al. [10]. We
could not demonstrated any differences in peak E2 levels,
fertilization rate, number of embryos transferred or im-
plantation and pregnancy rates, between the two luteal
support regimens [11]. Of notice, that in both groups of
luteal support following GnRH-a trigger, implantation and
pregnancy rates were lower compared to HCG trigger [7].
One bolus of 1500 IU hCG 35 h after the triggering
bolus of GnRHa, i.e. one hour after oocyte retrieval [10],
was demonstrated to rescue the luteal phase, resulting in
a reproductive outcome comparable with that of HCG
triggering, and with no increased risk of OHSS [12,13].
Moreover, in their recent review on GnRHa triggering,
Kol and Humaidan [8] have suggested, that once a deci-
sion to use GnRHa trigger has been made, the options
of fresh transfer and low-dose HCG supplementation,
should not be implemented to patients “at high risk to
develop OHSS”, such as those with >25 follicles. In a re-
cently published retrospective study, Seyhan et al [14] have
challenged the safety of the GnRHa trigger with HCG res-
cue. They examined whether GnRHa trigger and 1500 IU
hCG luteal rescue protocol, completely prevented severe
OHSS. Of the 23 patients evaluated, 6 (26%) developed se-
vere OHSS, 5 of whom had severe early OHSS requiring
ascites drainage and hospitalization. Moreover, a closer
look at the cycle characteristics of those who developed
severe early OHSS, 4 out of 5 had ≤25 follicles- a safe
threshold according to Kol and Humaidan [8]. Moreover,
their peak E2 levels and the number of oocytes retrieved
ranged between 2563 to 8364 pg/mL, and 23 to 65,
respectively.
The crucial issue, to our opinion, is how to recognize
patients at risk for OHSS, and whether >25 follicles is
an accurate and reliable predictive measure to identify
patients at risk for OHSS? The ideal strategy that will
eliminate OHSS without compromising ART outcome
is still under search.Prediction of OHSS
Navot et al. [15] have reviewed the epidemiological, hor-
monal, and ultrasonographic characteristics of patients
prone to develop OHSS. These included, among others,
patients with an excessively high E2 response (>4000-
6000 pg/ml, in IVF cycles) on the day of hCG adminis-
tration and with multiple (more than 35) small and
intermediate follicles that will yield more than 30 oocytes
on retrieval. These characteristics were further supported
by Asch et al. [16] who demonstrated that the combin-
ation of E2 levels >6000 pg/ml on the day of hCG admin-
istration and more than 30 retrieved oocytes is associated
with an 80% chance of developing severe OHSS, while an
almost negligible risk of OHSS was observed in IVF cycles
with serum E2 <3500 pg/ml and/or less than 20 oocytes
obtained at follicular aspiration. More than a decade
later, Papanikolaou et al. [17], while assessing predictive
values for identifying patients at risk for OHSS, revealed
that an optimal threshold of ≥13 follicles with a diam-
eter of >11 mm (85.5% sensitivity; 69% specificity) was
statistically significantly superior than E2 concentra-
tions of 2,560 ng/L (53% sensitivity, 77% specificity), on
day of HCG administration. Moreover, the combination
of a threshold of ≥18 follicles and/or E2 of ≥5,000 ng/L
yields a 83% sensitivity rate with a specificity as high as
84% for the severe OHSS cases [17].
Of emphasize, that while investigating randomized
controlled trials that aimed to prevent of severe OHSS,
we found that different studies defined high-risk patients
by different E2 threshold levels, ranging from 1906 to
6000 pg/ml, most used a level of ~3000 pg/ml [18]. More-
over, when all the predictive variables for severe OHSS
were combined, the prevalence of severe OHSS in the
ostensibly high risk patients was only about 20% [18]-
an extremely low value for a good predictive measure
(Detection rate with 80% false positive). This figure is
comparable to the 26% prevalence of severe OHSS, ob-
served in Seyhan study [14].Prevention of OHSS
Secondary prevention requires not only knowledge of the
pathophysiological mechanisms of the disease and means
of intervention to correct the pathophysiological changes,
but also the availability of early detection methods [19].
Since studies of the prevention of severe OHSS have been
limited by the low sensitivity and predictive values of the
factors currently used to define high risk [20], secondary
prevention is limited as well.
The key to preventing OHSS is experience with ovula-
tion stimulation therapy and recognition of “risk factors”
for OHSS. For high-responder patients undergoing their
first IVF attempt, it would be prudent to perform ovarian
stimulation with a GnRH antagonist which provides the
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ovulation, and thereby eliminating severe OHSS [4,7].
It is noteworthy, that by a strict adherence to our
previously published triage [4,21], we have already
been practicing an OHSS- Free clinic, for the last
8 years. However, for ensuring patient safety, we are
clearly paying by decrease ART outcome [7]. The re-
cent advents in the aforementioned modified methods
of the luteal support, have prompted us to improve our
triage, into a more strict, comprehensive and individually-
tailored approach to patients triggered with GnRHa. An
approach that will eliminate severe early OHSS, in one
hand, and will provide a reasonable pregnancy rate, in the
other.
Elimination of OHSS
Since neither excessive E2 levels, nor the number of devel-
oping follicles are reliable predictors for the development
of severe OHSS [22], a different prudent strategy should
be implemented.
In our practice, normal and high-responder patients
undergoing their first IVF attempt are offered the COH
with a GnRH antagonist (Figure 1). With this strategyNormal and high-resp
undergoing their 1st IV
COH with a GnRH
Transfer one embryo and the patient is 
instructed to continue intense luteal 
support
Signs of early OHSS
Freeze all policy Intensive lu
F
Patients at risk to develop 
severe OHSS
GnRHa- to trigger ovulation
OPU>20 oocytes OPU
Figure 1 IVF treatment in normal and high-responder patients underwe are able to substitute hCG with the GnRHa to trigger
ovulation. GnRHa trigger if offered to patients at risk to
develop severe OHSS. Those with rapidly rising serum
E2 levels; Peak E2 level in excess of 2,500 pg/mL; and/or
the emergence of a large number of intermediate sized
follicles [23].
Following the aforementioned observation regarding
GnRHa trigger with HCG rescue, we recently modified
our approach to those triggered with GnRHa instead of
HCG (Figure 1) [4]. In those achieving ≥20 oocytes, in
accordance with the center’s freezing experience, the
freeze all policy with the subsequent frozen-thawed em-
bryo transfers (ET), or the transfer of one embryo with
intense luteal support, are recommended. With the later, a
lower pregnancy rate is expected with no case of severe
OHSS.
If less than 20 oocytes are retrieved, patients are
instructed to start an intensive luteal support with
estradiol and progesterone, the day following OPU, and
are re-evaluated 3 days after oocyte retrieval (day of ET)
for signs of early moderate OHSS ((ultrasonographic
signs of ascites as reflected by the appearance of fluid
surrounding the uterus/ovaries, and/or Hct levels >40%onder patients 
F attempt
 antagonist
Patients not at risk to 
develop severe OHSS
HCG- to trigger ovulation
No signs of early OHSS
teal support with E2 and progesterone.
ollow 3 days post OPU
<20 oocytes 
Transfer one embryo and the patient is 
instructed to inject 1500 IU of HCG
and to continue intense luteal support
going their first attempt.
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moderate OHSS appear, one embryo is transferred, and
the patient is instructed to continue with the intense lu-
teal support. Of notice, lower pregnancy rates with no
case of severe OHSS are expected [7,11].
However, if no early signs of OHSS developed, one
embryo is transferred, and the patient is instructed to
inject 1500 IU of HCG. By deferring the hCG bolus by
3 days (5 days following GnRHa trigger), we are still
able to rescue the corpus luteum, with an observed
extremely high midluteal progesterone levels (Orvieto,
unpublished data). Moreover, we are actually offering
the hCG to 80% of the a priori at risk patients (the
aforementioned- detection rate c’ 80% false positive),
who are not supposed to develop severe early OHSS,
while avoiding hCG administration to the “real” 20-26%
[14,18] patient at risk to develop severe early-OHSS.
Despite a rather limited experience, no case of OHSS
has been encountered.
In patients in whom <20 oocytes were retrieved in the
first IVF cycle attempt, and in low responders or pa-
tients >40 years old, the COH protocol is individuallyElderly (>40 yrs old), low
achieving<20 oocytes in th
Individually tailored C
OPU>20 oocytes and or >10 embryos
Patient is instructed to start oral
carbegoline 0.5 mg a day for 8 days,    
and is followed for 5 days post OPU
Signs of early OHSS No 
Cryopreserve all embryos In patients <
transfer 1 bla
If HCG triggered If GnRH-ag triggere
follow Fig.1
Figure 2 IVF treatment in elderly (>40 yrs), poor responders and pati
attempt.tailored (Figure 2). If the tailored COH protocols (with
HCG trigger) yield ≥20 oocytes, or ≥10 embryos develop,
the patient is instructed to start oral cabergoline 0.5 mg a
day for 8 days [24], and is followed for 5 days after oocyte
retrieval for signs of early OHSS (see above). If early signs
develop, embryo transfer is withheld and all resulting
embryos cryopreserved. This approach limits early OHSS,
if it appears, to a milder and shorter form. If it does not
appear, we transfer one blastocyst, with the consequent
decrease in the risk of multiple pregnancy to almost zero,
thereby eliminating the risk of late OHSS.
Conclusion
COH using GnRH antagonist co-treatment and GnRHa
trigger, combined with 1500 IU hCG luteal rescue, is a
promising protocol, aiming to reduce (rather than elim-
inating) severe early OHSS, in on hand, and to improve
reproductive outcome, in the other. However, in the
meantime and until more studies elucidating the appro-
priate dose and timing of HCG administration will ap-
pear, strict adherence to the aforementioned strategy
(Figures 1 and 2) is suggested. responder and those        
eir previous IVF attempt
OH protocol
OPU<20 oocytes and 
or<10 embryos
Embryo transfer on day 2/3
signs of early OHSS
35 yrs old in one of their first 2 attempts,
stocyst. Otherwise, transfer 2 blastocysts
No pregnancy
d,       
ents in whom <20 oocytes were retrieved in the first IVF cycle
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